STOCK TITAN
  1. Home
  2. News
  3. SLNO

Soleno Therapeutics Inc - SLNO STOCK NEWS

Welcome to our dedicated news page for Soleno Therapeutics (Ticker: SLNO), a resource for investors and traders seeking the latest updates and insights on Soleno Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Soleno Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Soleno Therapeutics's position in the market.

News
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Soleno Therapeutics, a clinical-stage biopharmaceutical company, announced the grant of inducement awards to six new employees, as required by Nasdaq rules. The options have an exercise price of $37.90 per share and will vest over a four-year period.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Soleno Therapeutics, Inc. announced the grant of inducement awards to five new employees, with non-qualified stock options to purchase 144,300 shares of common stock. The options have an exercise price of $45.40 per share and will vest over a four-year period. This move aligns with Nasdaq Stock Market rules and aims to attract top talent to support Soleno's development of novel therapeutics for rare diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.69%
Tags
none
-
News
Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
Rhea-AI Summary
Soleno Therapeutics, Inc. provided a corporate update and reported financial results for Q4 and full-year 2023. The company announced positive data for DCCR in treating Prader-Willi syndrome, with plans to submit an NDA in mid-2024. They closed a public offering raising $129 million and strengthened their leadership team. Financially, Soleno had $169.7 million in cash as of December 31, 2023, with increased R&D and administrative expenses compared to the previous year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.09%
Tags
earnings
News
Soleno Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference
Rhea-AI Summary
Soleno Therapeutics, Inc. announces CEO presentation at TD Cowen 44th Annual Healthcare Conference, offering insights into rare disease therapeutics development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
News
Soleno Therapeutics to Present at Upcoming February Investor Conferences
Rhea-AI Summary
Soleno Therapeutics, Inc. announces CEO presentation at investor conferences and fireside chat, providing live audio webcast and replays on company website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.23%
Tags
conferences
-
News
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Soleno Therapeutics, Inc. announced the grant of inducement awards to five new employees, with an exercise price of $46.31 per share. The options will vest over a four-year period, subject to the employees' continued employment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.83%
Tags
none
News
Soleno Therapeutics Strengthens Leadership Team with Key Appointments
Rhea-AI Summary
Soleno Therapeutics, Inc. announced the appointments of key executives and advisors, including Meredith Manning as Chief Commercial Officer, Dairine Dempsey as Vice President, Europe, and Lauren Budesheim as Vice President of Human Resources. The company also appointed key advisors Shamim Ruff and James Geraghty. The new team brings extensive industry experience and expertise in global commercialization, regulatory affairs, and human resources. The appointments aim to strengthen capabilities in the U.S. and Europe as the company advances its DCCR therapy towards NDA and MAA filings for potential approval in Prader-Willi Syndrome.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.66%
Tags
management
-
News
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Soleno Therapeutics, Inc. (SLNO) announced the grant of inducement awards to three new employees, with 102,500 non-qualified stock options at an exercise price of $36.70 per share, vesting over a four-year period.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.23%
Tags
none
-
News
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Soleno Therapeutics, Inc. (NASDAQ: SLNO) announces the grant of inducement awards to two new employees. The Compensation Committee approved the grant of non-qualified stock options to purchase 145,000 shares of common stock at an exercise price of $21.93 per share. The options will vest over a four-year period, subject to continued employment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News
Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results
Rhea-AI Summary
Soleno Therapeutics, Inc. reported positive statistically significant top-line data from the randomized withdrawal period of Study C602, a long-term treatment study of DCCR for the treatment of Prader-Willi syndrome. Soleno's cash and cash equivalents were approximately $52.4 million as of September 30, 2023. They received gross proceeds of $169.9 million from recent financing activities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.48%
Tags
earnings
Stock SLNO logo
Soleno Therapeutics Inc

Nasdaq:SLNO

SLNO Rankings

#2255 Ranked by Market Cap
#1 Ranked by Stock Gains
N/A Ranked by Dividends

SLNO Stock Data

1.21B
13.17M
2.06%
97.44%
8.5%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
US
Redwood City

About SLNO

soleno therapeutics, inc. is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. the company is currently advancing its lead candidate, dccr, a once-daily oral tablet for the treatment of pws, into a phase iii clinical development program in early 2018.